Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Union Chamber Calls For Equal Access In China; Over A Trillion Euro In WTO Procurement At Stake

This article was originally published in The Pink Sheet Daily

Executive Summary

China is anxious to gain access to the collective market of the 40-plus members of the World Trade Organization's Government Procurement Agreement, but it must first drop barriers to its own markets.

You may also be interested in...

European Union Chamber Of Commerce In China Calls For An End To Protectionism And Discrimination

BEIJING - While acknowledging China's economic expansion despite the global financial crisis, the leaders of the European Union Chamber of Commerce in China are calling on Beijing to create a more level playing field for foreign-funded firms across the country

Massive U.S. Government Delegation Seeks Common Ground In China To Counter Threats To Peace And Health

BEIJING - One of the most extensive American government delegations to make a state visit to China - headed by Secretary of State Hillary Clinton and Treasury Secretary Tim Geithner - posted only sporadic progress this week across a spectrum of issues affecting ties between the globe's financially hobbled superpower and fastest rising economic force, yet the two sides renewed an important pact on jointly tracking and fighting infectious diseases that have the potential to crisscross the continents

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts